Project cooperationUpdated on 30 December 2025
PET imaging-guided new drug development
Professor at University of Turku
Turku, Finland
About
We provide novel radiopharmaceuticals and PET imaging techniques for monitoring treatment-response for your new drug development. We use PET technique to study in vivo stability and pharmacokinetics of new drugs, and to study disease mechanisms with the aid of PET imaging and quantification.
If you have a new drug candidate, we can radiolabel the drug molecule and use PET to study and quantify its pharmacokinetics and biodistibution in the whole body with a single PET scan. In addition, we can monitor the treatment-response of your drug candiate non-invasively in a longitudinal manner.
If you would study a drug target, we can use PET to quantify your drug target expression in the whole body under different disease stages.
We use in vivo approaches to study and quantify sex difference in drug response.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Maria Kitsara
Science and Innovation Manager at BIOEMTECH
Gerakas Attikis, Greece
Project cooperation
New in vitro assay methodologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Hanne Haslene-Hox
Seinor research scientist at SINTEF Industry
Trondheim, Norway
Project cooperation
Translational NAMs in pharmacology & toxicology for drug profiling
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Nikolas Dietis
Assistant Professor of Pharmacology at University of Cyprus
Nicosia, Cyprus